Pulmonary tumor thrombotic microangiopathy: FDG-PET/CT findings

Yoshiko Tashima1, Koichiro Abe, Yoshio Matsuo

  • 1Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Insights

Pulmonary tumor thrombotic microangiopathy (PTTM) is a fatal condition causing severe cardiopulmonary failure. Characteristic findings on 2-(F-18)-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) imaging can aid in its diagnosis.

Area of Science:

  • Oncology
  • Radiology
  • Pathology

Background:

  • Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare and fatal condition.
  • Histopathological hallmarks include myofibroblast proliferation in pulmonary arterioles due to tumor microemboli.
  • PTTM leads to rapid, severe cardiopulmonary failure with a poor prognosis.

Observation:

  • Conventional imaging often shows minimal or nonspecific findings.
  • Diagnosis of PTTM is challenging before death.
  • This study reports on 2-(F-18)-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) imaging in PTTM.

Findings:

  • FDG-PET imaging demonstrates characteristic findings in PTTM.
  • The specific FDG-PET patterns can help identify this clinical entity.
  • This offers a potential diagnostic tool for PTTM.

Implications:

  • FDG-PET may improve the diagnostic accuracy of PTTM.
  • Earlier diagnosis could potentially lead to timely interventions.
  • This highlights the utility of advanced imaging in diagnosing rare oncological complications.